This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
5 ETFs to Make the Most of Eli Lilly's Strength
by Sweta Killa
Impressed by Eli Lilly's (LLY) blowout earnings, several analysts raised their target price on the stock.
ETFs to Secure Your Portfolio Amid Uncertain Market Conditions
by Yashwardhan Jain
With the markets recently experiencing a sharp sell-off which may have dampened investor confidence, increasing bets that the U.S. economy may slip into a recession increases the need to safeguard investor portfolios with defensive bets.
Should You Invest in the iShares U.S. Healthcare ETF (IYH)?
by Zacks Equity Research
Sector ETF report for IYH
What Lies in Store for Healthcare ETFs in Q2 Earnings?
by Sweta Killa
The healthcare sector has gained momentum lately on market rotation, with investors rushing to buy beaten-down stocks while shunning the hot technology sector.
UnitedHealth Rises on Q2 Earnings Beat: ETFs to Gain
by Sweta Killa
UnitedHealth Group (UNH) reported better-than-expected second-quarter 2024 results as it breezed past the Zacks Consensus Estimate on both earnings and revenues.
Should You Invest in the iShares U.S. Healthcare ETF (IYH)?
by Zacks Equity Research
Sector ETF report for IYH
ETFs to Buy as Eli Lilly Beats Q1 Earnings, Lifts Outlook
by Sweta Killa
Eli Lilly and Company (LLY) raised its outlook for 2024 on rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro.
Will Healthcare ETFs Lose Momentum as Q1 Earnings Unfold?
by Sweta Killa
While the healthcare sector is expected to benefit from cutting-edge medicines, new drug approvals, technological advancements, and deal activities, it is expected to witness a modest earnings decline of 5.6% in the first quarter.
UnitedHealth Rises on Q1 Earnings Beat: ETFs to Gain
by Sweta Killa
UnitedHealth Group (UNH) breezed past the Zacks Consensus Estimate on both earnings and revenues.
JNJ Beats Q1 Earnings Estimates, Misses on Sales: ETFs in Focus
by Sweta Killa
Johnson & Johnson (JNJ) continued with its long streak of earnings beat but lagged revenue estimates.
Time to Tap Healthcare ETFs on Nvidia's AI Ambition?
by Sanghamitra Saha
At Nvidia's last week's GTC AI conference, the company announced partnerships in the healthcare sector, representing a strategic move toward expanding its revenue streams beyond tech sectors.
Should You Invest in the iShares U.S. Healthcare ETF (IYH)?
by Zacks Equity Research
Sector ETF report for IYH
Buffett's Wisdom: 6 ETF Strategies for Investors
by Sanghamitra Saha
Follow Warren Buffett's latest tips and bet on these ETFs.
ETFs to Buy as Mounjaro Powers Eli Lilly's Q4 Earnings Beat
by Sweta Killa
Eli Lilly and Company (LLY) posted robust fourth-quarter 2023 earnings, beating estimates on both the top and bottom lines driven by strong sales of its diabetes and weight-loss treatments.
Should You Invest in the iShares U.S. Healthcare ETF (IYH)?
by Zacks Equity Research
Sector ETF report for IYH
UnitedHealth Beats on Q4 Earnings, Shares Slip: ETFs in Focus
by Sweta Killa
The largest U.S. health insurer UnitedHealth Group (UNH) reported better-than-expected fourth-quarter 2023 results but medical costs rose more than expected for the first time in two years.
Healthcare ETFs Start 2024 on a Positive Note
by Sweta Killa
After underperforming in 2023, the healthcare sector seems to be back on track at the start of the New Year. Healthcare generally outperforms during periods of low growth and high uncertainty.
ETFs to Secure Your Portfolio Amid Potential Economic Fluctuations
by Yashwardhan Jain
The possibility of a mild recession, rising fears of an economic slowdown and significant debt levels are some possible headwinds that could dampen the prospects of the economy in 2024. Look into funds to benefit from such a situation.
Should You Invest in the iShares U.S. Healthcare ETF (IYH)?
by Zacks Equity Research
Sector ETF report for IYH
Eli Lilly Beats on Q3 Earnings: ETFs to Buy
by Sweta Killa
Eli Lilly (LLY) posted robust third-quarter 2023 earnings results, beating estimates on both the top and bottom lines. Its Mounjaro anti-obesity drug continued its robust performance.
JNJ Beats Q3 Earnings Estimates, Raises View: ETFs in Focus
by Sweta Killa
The world's biggest healthcare products maker continued with its long streak of earnings beat and lifted the full year outlook.
UnitedHealth Beats on Q3 Earnings, Raises View: ETFs to Gain
by Sweta Killa
UnitedHealth (UNH) reported better-than-expected third-quarter 2023 results. Earnings and revenues breezed past the Zacks Consensus Estimate. The company also lifted the lower end of its full-year earnings guidance.
Should You Invest in the iShares U.S. Healthcare ETF (IYH)?
by Zacks Equity Research
Sector ETF report for IYH
Eli Lilly Soars on Blockbuster Q2 Earnings: ETFs to Tap
by Sweta Killa
Eli Lilly (LLY) experienced its most significant surge in stock prices in over two decades following the release of an impressive second-quarter 2023 earnings report and an optimistic outlook. ETFs having the largest exposure to the drug maker could be compelling picks to tap the strong growth.
5 ETFs to Buy on JNJ's Q2 Earnings Strength
by Sweta Killa
Johnson & Johnson (JNJ) continued with its long streak of earnings beat. It topped the revenue estimate as well as lifted the full-year outlook.